Pages

Wednesday, 11 February 2015

Spin-off #2: Indivior

Just before Christmas I wrote up the spin-off of Indivior from its parent company, musing whether it was potentially good value or not (I did subsequently initiate a position albeit a relatively small one as my investigations continued).  Even though the share has has been volatile today (day's range of 133-167p!) from the mid 140p level I initially purchased the shares at before Christmas it has been a winner.



The inaugural listed results are always an important point of any new company to the market and it is noteworthy how the company described itself:

Typically when you see 'enormous future potential' this is short-hand for shabby near-term results and on that front this guide was absolutely correct.  I discussed at the above link before Christmas some of the challenges the group was facing and they nicely summarised some of these in an early slide from their presentation pack: 


Share losses, 'forced switching' and price reductions is rarely a good miss but not totally surprising given the profile of company established at the time of its spin-off.  Competition has kicked in and, as noted below, 'will intensify'...


...and hence the key product market share of Suboxone (the background to which is discussed at more length at the link above) is seeing fading market share but it is broadly fair to describe it as 'resilient':

Pull all of this together and revenues are anticipated to fall over 20%...and unsurprisingly net income in a geared fashion much more than this.  

So is the share cheap?  Well with an EV of around £1.4bn the implied EV/ebit (generated using the 29% tax rate guided to by the company for 2015) is just over x10 for FY15.  The free cash flow yield (historically 80%+ of operating profit) is a reasonably healthy c. 8% which no doubt contributes to management's second assertion below that: 


Back in December in my initial piece I noted that the company's pipeline products are focused on later in the decade albeit that the first product (Nasal Naloxone) is twelve months away.  If you are looking for the source of upside it is undoubtedly here.  There may also be some dividend benefit in 2015 as the company looks to assuage concerns used to the Reckitts dividend flow.  

What I also liked about the inaugural results presentation document was that the Indivior management are clearly trying to help educate (potential) investors with two presentation slides full of helpful academic and related information to assist in monitoring the company plus a further two slides encompassing the forward calendar of meetings, presentations and corporate results.  It is a shame other companies do not make such efforts.  

Pulling it all together, Indivior remains speculative but interesting.  The shareholder base is clearly calming down and the apparent support for the share in the 130s/140s is worthy of note.  Clearly there are uncertainties but to have no position feels wrong.  This is a company in transition and it is not well-known (or covered).  

With more information now it is clear that the extent of the undervaluation is not as material as I thought in December but risk-reward still feels sufficient to at least maintain my position in this (unfortunately addiction centred) fascinating theme stock 

No comments:

Post a Comment